Form 4: CorMedix CLO Acquires 69,686 Shares in RSU Grant

CorMedix Inc.'s Chief Legal Officer, Beth Zelnick Kaufman, was granted 69,686 restricted stock units, increasing her beneficial ownership to 189,298 shares.

Summary

• Beth Zelnick Kaufman, Chief Legal Officer of CorMedix Inc., acquired 69,686 shares of common stock.
• These shares were granted as Restricted Stock Units (RSUs) on August 29, 2025.
• The RSUs vested 1/4 on the date of grant, and will vest 1/4 on the first, second, and third anniversaries of the grant date, subject to continued employment.
• Following this transaction, Ms. Kaufman beneficially owns 189,298 shares of CorMedix Inc. common stock.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a key executive is generally a positive signal, indicating management retention and alignment of interests with shareholders. While not a direct open-market purchase, it reflects ongoing commitment and incentivizes long-term performance.

Positives

• Chief Legal Officer Beth Zelnick Kaufman increased her beneficial ownership in CorMedix Inc. by 69,686 shares through a restricted stock unit grant.
• The grant aligns management's interests with shareholders through long-term equity incentives and executive retention.

Future Outlook

The vesting schedule for the restricted stock units indicates a long-term retention strategy for the Chief Legal Officer, with shares vesting over three years, subject to continued employment.

Industry Context

Equity grants to key executives are a standard practice across the pharmaceutical and biotechnology industries to incentivize long-term performance and align management interests with shareholder value creation.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) with a multi-year vesting schedule is a common compensation practice for executive retention in the biotechnology sector, similar to programs at companies like Pfizer, Moderna, or Johnson & Johnson, which often use equity to tie executive compensation to company performance and longevity.
• The specific vesting schedule of 1/4 on grant date and then annually over three years is a typical structure designed to encourage long-term commitment and performance from key personnel, aligning with industry norms for executive incentive plans.

Stakeholder Impact

• Shareholders: The grant of equity to a key executive aligns management's long-term interests with shareholder value creation, potentially fostering stability and strategic focus.
• Employees: The compensation structure for the Chief Legal Officer may serve as a benchmark or signal for other executive compensation practices within the company.

Next Steps

• Continued vesting of the remaining restricted stock units on the first, second, and third anniversaries of the grant date, subject to Beth Zelnick Kaufman's continued employment.

Key Dates

Recommendation

This Form 4 reports a routine restricted stock unit grant to a key executive, which is a standard compensation practice for retention and alignment. It does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. Investors should continue to hold based on broader company fundamentals rather than this specific insider transaction.

Keywords

CorMedix Inc., CRMD, Beth Zelnick Kaufman, Chief Legal Officer, Restricted Stock Units, RSU, Insider Transaction, Equity Grant, Beneficial Ownership, Executive Compensation